Difference between revisions of "Carbonic anhydrase inhibitor"
m |
m (1 revision) |
(No difference)
| |
Latest revision as of 15:44, 19 September 2010
Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as antiglaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, neurological disorders, or osteoporosis. [1][2][3]
Types
Acetazolamide is an inhibitor of carbonic anhydrase. It is used for glaucoma, epilepsy (rarely), benign intracranial hypertension, and altitude sickness. It can act as a mild diuretic by reducing NaCl and bicarbonate reabsorption in the proximal tubule. However, the distal segment partially compensates for the sodium loss, and the bicarbonaturia will produce a metabolic acidosis, further reducing the effect.
Methazolamide is also a carbonic anhydrase inhibitor. It has a longer elimination half-life than acetazolamide and is less associated with adverse effects to the kidney.[4][5][6]
Dorzolamide is a sulfonamide) and topical carbonic anhydrase II inhibitor. It is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and who are insufficiently responsive to beta-blockers. Inhibition of carbonic anhydrase II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Topiramate is a weak inhibitor of carbonic anhydrase, particularly subtypes II and IV. It is a sulfamate-substituted monosaccharide, related to fructose. In the US, it is approved by the U.S. Food and Drug Administration (FDA) as an anticonvulsant to treat epilepsy and Lennox-Gastaut syndrome, and also to treat migraine headaches. In rare cases, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
es:Inhibidores de la anhidrasa carbónica
pl:Inhibitory anhydrazy węglanowej- ↑ Supuran, C.T.; Scozzafava, A.; Conway, J. (Eds.): Carbonic anhydrase - Its inhibitors and activators, CRC Press, Boca Raton (FL), USA, 2004; pp. 1- 363
- ↑ Supuran, C.T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat., 2000, 10, 575-600.
- ↑ Supuran, C.T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev., 2003, 23, 146-189.
- ↑ Bennett WM, Aronoff GR, Golper TA, et alBennett WM, Aronoff GR, Golper TA, et al.: Drug Prescribing in Renal Failure, American College of Physicians, Philadelphia, PA, 1987
- ↑ Product Information: Neptazane(R), methazolamide. Storz Ophthalmics Inc, Clearwater, FL, 1995a
- ↑ Reynolds JEF (Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc. Englewood, CO. 1995.
